These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 16138566

  • 1. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T, Kobayashi T, Honda T, Takahashi M, Minami J, Ohta S, Inada H, Yoshii M, Ono H, Matsuoka H.
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.
    Clin Exp Hypertens; 2012 Apr; 34(4):249-57. PubMed ID: 22571446
    [Abstract] [Full Text] [Related]

  • 3. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T, Fujimoto A, Nakao K, Saruta T, CASE-J Trial Group.
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N, Fujino T, Kabara M, Matsuki M, Chinda J, Kikuchi K, Hasebe N, NICE-Combi Study Group.
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 6. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.
    Nephron Clin Pract; 2005 Jan; 99(1):c18-23. PubMed ID: 15637459
    [Abstract] [Full Text] [Related]

  • 7. Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients.
    Uno H, Ishikawa J, Hoshide S, Kabutoya T, Ishikawa S, Shimada K, Kario K.
    Hypertens Res; 2008 May; 31(5):887-96. PubMed ID: 18712044
    [Abstract] [Full Text] [Related]

  • 8. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A, Tamura K, Dejima T, Ozawa M, Wakui H, Masuda S, Azuma K, Tsurumi-Ikeya Y, Mitsuhashi H, Okano Y, Kokuho T, Sugano T, Ishigami T, Toya Y, Uchino K, Tokita Y, Umemura S.
    Nephron Clin Pract; 2009 May; 112(1):c31-40. PubMed ID: 19342867
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J, Shojaee A, Maa JF.
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II Investigators.
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 12. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Nakamura T, Kanno Y, Takenaka T, Suzuki H, Efficacy of Candesartan on Outcome in Saitama Trial Group.
    Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
    [Abstract] [Full Text] [Related]

  • 13. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S.
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [Abstract] [Full Text] [Related]

  • 14. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T.
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R, Hagiwara N, Yamaguchi J, Kawada-Watanabe E, Haruta S, Takagi A, Ogawa H, HIJ-CREATE Investigators.
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [Abstract] [Full Text] [Related]

  • 16. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 17. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker.
    Kamezaki F, Tasaki H, Yamashita K, Shibata K, Hirakawa N, Tsutsui M, Kouzuma R, Nagatomo T, Adachi T, Otsuji Y.
    Hypertens Res; 2007 Aug; 30(8):699-706. PubMed ID: 17917317
    [Abstract] [Full Text] [Related]

  • 19. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 20. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG, Serbul VM, Ageev FT.
    Ter Arkh; 2009 Jun; 81(5):64-71. PubMed ID: 19537590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.